Clinical Trial

A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated January 28, 2026 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a Phase 2, double-blind, parallel-group, placebo-controlled study to assess safety, tolerability, pharmacokinetics, and efficacy of ONO-2020 in participants with mild to moderate Alzheimer's disease (AD). This study aims to determine whether administering ONO-2020, an epigenetic regulator, may improve cognitive functions like memory and cognition in individuals with Alzheimer's disease dementia.
Protocol Amendment History 1 change
notable Sponsor changed: Ono Pharmaceutical Co. Ltd -> Ono Pharmaceutical Co., Ltd. 2026-04-19
Trial Details
NCT Number NCT06881836
Lead Sponsor Ono Pharmaceutical Co. Ltd
Conditions Alzheimer Disease
Enrollment 240 participants
Start Date 2025-04-24
Primary Completion 2026-07 (estimated)
Study Completion 2026-08 (estimated)
Updated on ClinicalTrials.gov 2026-01-28